Effects of growth hormone treatment after final height in Prader-Willi Syndrome
- Conditions
- Prader-Willi SyndromePrader-Willi Syndroom
- Registration Number
- NL-OMON28633
- Lead Sponsor
- Dutch Growth Foundation
- Brief Summary
n/a
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1. Young adults, originally participating in the Dutch GH study in PWS children (ISRCTN49726762) or otherwise GH-treated patients and
2. Final height is reached or epiphysial fusion is complete and
3. Treated with GH during childhood for at least 2 years
Exclusion Criteria
1. non cooperative behaviour
2. extremely low dietary intake of less than minimal required intake according to WHO
3. medication to reduce weight (fat)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess effects of GH-treatment versus placebo on<br>a. body composition<br>b. carbohydrate metabolism<br>c. psychosocial functioning<br>d. sleep-related breathing disorders<br>e. circulating lipids<br>f. blood pressure<br>
- Secondary Outcome Measures
Name Time Method 1. To study the effects of GH-treatment versus placebo on thyroid hormone levels, IGF-I and IGF binding proteins, adiponectin, ghrelin.<br>2. To study compliance to the diet.<br>